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MitochondriaDiabetes has emerged as an epidemic of the 21st century, and retinopathy remains the leading cause of blindness
in young adults and themechanism of this blinding disease remains evasive. Diabetes-inducedmetabolic abnor-
malities have been identiﬁed, but a causal relationship between any speciﬁc abnormality and the development of
this multi-factorial disease is unclear. Reactive oxygen species (ROS) are increased and the antioxidant defense
system is compromised. Increased ROS result in retinal metabolic abnormalities, and these metabolic abnormal-
ities can also produce ROS. Sustained exposure to ROS damages themitochondria and compromises the electron
transport system (ETC), and, ultimately, themitochondrial DNA (mtDNA) is damaged. DamagedmtDNA impairs
its transcription, and the vicious cycle of ROS continues to propagate. Many genes important in generation and
neutralization of ROS are also epigenetically modiﬁed further increasing ROS, and the futile cycle continues to
fuel in. Antioxidants have generated beneﬁcial effects in ameliorating retinopathy in diabetic rodents, but limited
clinical studies have not been encouraging. With the ongoing use of antioxidants for other chronic diseases, there
is a need for a controlled trial to recognize their potential in ameliorating the development of this devastating disease.
© 2015 Published by Elsevier B.V.1. Introduction
Diabetes, a metabolic disease in which the ability of the body to
properly utilize the glucose is impaired, is now emerging as an epidemic
of the 21st century. Glucose utilization could be impaired either due to
lack/reduction in insulin production (type I diabetes) or due to body's
ability to utilize insulin (type II diabetes). Although hyperglycemia in
these two forms of diabetes is the outcome of two different reasons,
over time, it causes a number of health problems in both type I and
type II diabetic patients. According to International Diabetes Federation,
every 7 s a person dies from diabetes. With the number of patients
afﬂicted with this chronic disease is rising at an alarming rate, diabetes
has become a major public health issue. According to International dia-
betes federation, 382 million people worldwide have diabetes, and this
number is projected to rise to 592 million in less than 25 years [1]. In
this life-long disease, sustained high circulating glucose damages the
vasculature resulting in chronic micro- and macro-vascular complica-
tions throughout the body. Damage to the macrovasculature increases
the prevalence of heart disease, stroke and peripheral arterial disease,
and to themicrovasculature, in retinopathy, neuropathy and nephropa-
thy in diabetic patients.yne State University, 4717 St.
luru).2. Diabetic retinopathy
Retinopathy, one of themajormicrovascular complications of diabe-
tes, is considered as the most feared complications among the young
adults, and it is the leading cause of acquired blindness in working age
adults. Sustained hyperglycemia damages the microvascular bed of
the retina, the innermost layer of the eye, ultimately impairing its ability
to convert light signals. This is a duration-dependent disease, which is
rarely detected within the ﬁrst few years of diabetes, but its incidence
dramatically increases with time, and after 20–25 years of diabetes
almost 90% of patients present some signs of retinopathy [2]. With the
recent advancement in blood glucose management and increase in
awareness of the disease, the incidence and the risk of progression of
diabetic retinopathy is on a descending end; the population-based
Wisconsin Epidemiologic Study of Diabetic Retinopathy has document-
ed 77% decrease in the estimated annual incidence of proliferative dia-
betic retinopathy between 1998–2007 [3]. However, with the increase
in the incidence of diabetes at an alarming rate, the number of people
with diabetic retinopathy is also projected to grow from 126.6 million
in 2010 to 191.0 million by 2030. Based on current estimates, increase
in the number with vision-threatening diabetic retinopathy is projected
to increase from 37.3 million to 56.3 million [4], and it is critical to un-
derstand the mechanism of its development.
Microvasculature of the retina is the major site of pathology associ-
ated with diabetic retinopathy [2]. The retina, a light-sensitive layer of
tissue which lines the inner surface of the eye, is themostmetabolically
active tissue in the body. Through a cascade of chemical and electrical
reactions, it converts light into nerve impulses, and optic nerve
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with a number of layers and cells types. The major cell types in the ret-
ina are the vascular cells (pericytes and endothelial cells), macroglial
cells (Muller cells and astrocytes), neurons (photoreceptors, bipolar
cells, amacrine and ganglion cells), and microglia (which act as phago-
cytes). The vasculature of the retina occupies the inner half of the neural
retina, and is a highly organized structure. The innermost portion of the
retina contains the larger vessels and the space between the nerve ﬁber
and inner nuclear layer is occupied by themicrovasculature. The retinal
capillaries are surrounded by a connective tissue sheath, the basement
membrane, and inside the capillaries is a lining of endothelial cells. En-
dothelial cells form connections between each other, and these tight
junctional complexes act as barrier between the retina and the blood
circulation. Tight junctions impede the outward ﬂow of macromole-
cules, and maintain the microenvironment [5]. However, in diabetes,
disruption of blood-retinal barrier allows albumin and othermacromol-
ecules to leak out into the vitreous. The capillaries are covered by a layer
of smooth muscle cells, pericytes; these cells help in contraction to reg-
ulate retinal vascular tone and blood ﬂow. Diabetic environment
thickens the basement membrane and accelerates the loss of pericytes
and endothelial cells and damages the vasculature [2,6].
Diabetic retinopathy is a slow progressing disease, in the initial
stages, it is asymptomatic and the patients may have 20/20 vision. In
this non proliferative stage, microaneurysms (very small blood-ﬁlled
bulges) are visible by fundus photography, and ﬂuorescein angiography
could show some leakage. The patients might experience thickening of
the macula, and due to macular edema, vision becomes blurred. This
nonproliferative stage of diabetic retinopathy, if not controlled, could
progress to proliferative diabetic retinopathy, where neovascularization
appears at the back of the eye and extend into the vitreous of the eye,
and these new blood vessels begin to bleed scaring the vitreous body
leading to retinal detachment, and ultimately to blindness [2].
Animal studies have shown that in the early stages of the disease, the
basement membrane of the capillaries is thickened; pericytes are lost
before any histopathological signs begin to appear. Loss of pericytes
makes capillaries collapse, and endothelial cells begin to die [6]. Al-
though impaired retinal function is reported in diabetic patients and
in animal models of diabetic retinopathy before appearance of any his-
topathology characteristic of diabetic retinopathy, the disease has large-
ly been relatedwith themicrovasculature of the retina. Recentwork has
suggested that the neuronal unit of the retina is also intimately associat-
ed with diabetic retinopathy as retinal neurons and glial cells also show
biochemical defects and functional abnormalities, including accelerated
apoptosis of neurons, activation of microglial cells and increased pro-
duction of oxidative stress by photoreceptors [7]. Furthermore, with
the worsening of diabetic retinopathy, these neuronal lesions also
show progressive impairments. But, how these neuronal abnormalities
contribute to the histopathology characteristic of diabetic retinopathy
remains unclear.
3. Molecular mechanisms of diabetic retinopathy
Diabetic retinopathy is a multi-factorial disease with a complex
etiology. Diabetes Control and Complications Trial (DCCT), and follow
up Epidemiology of Diabetes Interventions and Complications (EDIC)
studies, have clearly documented the importance of good glycemic con-
trol in inhibiting/preventing the development of diabetic retinopathy,
and early intervention remains crucial to prevent its further progression
[8]. Similar results are also demonstrated in in vitro and in vivomodels of
diabetic retinopathy [9–13]. However, maintenance of good glycemic
control for this life-long disease is, at times, could be challenging, and
unachievable, and to identify a therapeutic target, understanding the
mechanisms becomes very important. Although hyperglycemia re-
mains the main instigator of the development of diabetic retinopathy,
other systemic factors, including dyslipidemia and hypertension are
also associated with its development [14]. Despite extensive ongoingresearch in the ﬁeld to understand the etiology of this complex disease,
the exact mechanism responsible for its development remains elusive.
In vivo and in vitro models of diabetic retinopathy have identiﬁed
manymetabolic abnormalities, and someof themajor pathways include
activation of advanced glycation end products (AGEs) formation, polyol
and hexosamine pathways and protein kinase C (PKC), and increase in
oxidative stress [15–19].
Diabetic environment facilitates the interactions of glucose with
amino acids in proteins, lipids and nucleic acids, and via non-
enzymatic reactions, form Schiff's base and Amadori products [19]. A
complex cascade of reactions, ultimately results in the conversion of
Amadori products into the formation of AGEs [20]. Increased AGEs and
their receptors (RAGEs) are observed within retinal capillaries, and are
associatedwith increased inﬂammation and capillary cell loss in diabet-
ic retinopathy [21]. Furthermore, the gene encoding RAGEs is consid-
ered to serve as a surrogate marker for patients vulnerable to diabetic
complications [22].
Excess glucose is converted to sorbitol by aldose reductase, an en-
zyme which uses nicotinamide adenine dinucleotide phosphate
(NADPH) as a hydrogen donor and has a high ‘Km’ for glucose. Because
of consumption of NADPH, its availability for the biosynthesis of intra-
cellular antioxidant glutathione (GSH) is decreased. Sorbitol dehydro-
genase further converts sorbitol to fructose by utilizing NAD+ as a
hydrogen donor [15]. Increased polyol pathway activity is seen in the
retina and its capillary cells in diabetes, and genetic association between
the C allele of the polymorphism at position−106 in the promoter of
aldose reductase gene AKR1B1 and diabetic retinopathy [23]. However,
the exactmechanismbywhich polyol pathway plays a role in the devel-
opment of diabetic retinopathy remains elusive, and clinical trials using
aldose reductase inhibitors have been inconclusive [24].
Increased levels of circulating glucose are shown to activate diacyl
glycerol-PKC cascade, and PKC activation in retinal vasculature is impli-
cated in increased vascular permeability, alterations in blood ﬂow and
stimulation of neovascularization seen in diabetic retinopathy [25].
PKC is also implicated in the acceleration of apoptosis of capillary cells,
resulting in degenerative capillaries and pericyte ghosts, the early histo-
pathological signs seen in animal models of diabetic retinopathy [25].
Thus, the importance of understanding how hyperglycemia alters mul-
tiple pathways through changes to only a few essential cellular ele-
ments is very critical. PKC inhibitor, ruboxistaurin, has shown
encouraging initial results in attenuating retinal hemodynamic abnor-
malities in diabetic patients, clinical trials have not been very promising
[26].
The ﬂux of fructose 6-phosphate into the hexosamine pathway is
also increased in diabetes, and activation of this pathway serves as an al-
ternative to glycolysis to utilize overproduction of fructose 6-phosphate
[15]. Activation of hexosamine pathway is implicated in apoptosis of
retinal capillary cells in diabetes [27], and in limiting pericyte
proliferation.
Circulating high glucose is closely related to increase in oxidative
stress, and the retina being a tissue rich in polyunsaturated fatty acids
with high glucose oxidation and oxygen uptake [28], is considered as
a good target of increased oxidative stress in diabetes. Increased oxida-
tive stress, the major focus of this review, is postulated in the develop-
ment of major diabetic micro- and macro-vascular complications of
diabetes. Increase in oxidative stress is associated with a wide range of
microvascular abnormalities associated with the development of dia-
betic retinopathy including, cell loss, hemodynamic and structural
changes and basement thickening [15–18,29,30]. Increased serum
lipid hydroperoxides are also associated with increased prevalence of
retinopathy in diabetic patients [31]. In addition to circulating high
glucose itself, reactive oxygen species (ROS) are also produced by
other diabetes-induced metabolic abnormalities including activation
of PKC and AGEs [15,32].
Activation of these pathways is considered to stem fromhyperglyce-
mia and the accumulation of various glycolytic intermediates. A link
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abetic retinopathy, however, remains largely speculative, raising the
possibility that no single metabolic abnormality could be responsible
for development of this complex disease.
4. Oxidative stress
Normal cellular metabolism continuously produces free radical; the
body utilizes ~95% of them for metabolism and 5% of the oxygen is con-
verted into ROS. These ROS act as double edged sword; they canwork as
messengers in redox signaling, but can also damage normal cellular sig-
naling. A very efﬁcient antioxidant defense system with enzymatic and
non-enzymatic antioxidants effectively detoxiﬁes these dangerous ROS.
However, under pathological conditions, production and detoxiﬁcation
of free radicals is impaired, due to either increased ROS production or
decreased removal, or both, resulting in an imbalance between produc-
tion and destruction of ROS create an excessive bioavailability of ROS. If
these damaging free radicals are not readily neutralized, they damage
macromolecules-proteins, lipids and DNA, and alter the expression of
various stress-response genes further stimulating additional ROS gener-
ation from endogenous sources [33]. As mentioned above, enzymatic
andnonenzymatic antioxidants are available to defend from the damag-
ing effects of ROS. In diabetic retinopathy, the retina experiences both,
increased production and decreased removal of free radicals [34].
5. Sources of oxidative stress
Both enzymatic and non-enzymatic mechanisms produce superox-
ide radicals, while cytosolic NADPH oxidase (Nox) is the primary en-
zyme responsible for their production [30], non-enzymatic production
is mainly the consequence of mitochondrial respiration. Nox, a multi-
protein enzyme, catalyzes one-electron reduction of oxygen to superox-
ide anion, and the process involves oxidization of cytosolic NADPH to
NADP. In diabetes, increased activity of Nox is observed inmany tissues,
including pancreatic beta cells and retina, suggesting it to be one of the
major sources of ROS generation [17,30].
Arginase is another important instigator of oxidative stress as in-
creased arginase activity causes endothelial nitric oxide synthase
(eNOS) uncoupling due to decreased levels of L-arginine, and uncoupled
eNOS produces superoxide which reacts with available nitric oxide to
form peroxynitrite. In diabetes, increased arginase in the retina is
shown to be associated with endothelial cell dysfunction [35]. Further-
more, peroxynitrite, via protein tyrosine nitration, can also enhance
the activity of NADPH oxidase, which can further fuel to increased ROS
production.
6. Mitochondria and generation of superoxide
Mitochondria are the major source of free radicals; in normal phys-
iological conditions, this account for approximately 2% of the total oxy-
gen uptake. Electron transfer through complexes I, III and IV of the
electron transport chain pump protons into the inter membrane
space, generating a proton gradient that drives ATP synthase, but
some electrons leak out from complex I or complex III, and interact
with molecular oxygen to form superoxide anion [36]. Furthermore,
acyl-CoA dehydrogenase and glycerol phosphate dehydrogenase also
generate ROS [37], and increased glucose-derived pyruvate is oxidized
in the tricarboxylic acid cycle, which increases the ﬂux of electron do-
nors into the electron transport chain. This overwhelms the electron
transport chain and blocks the electron transfer inside complex III, caus-
ing the electrons to back up to coenzyme Q, and increasing free radical
levels [38]. In the pathogenesis of diabetic retinopathy, inactivation of
complex III activity is implicated in increasedmitochondrial superoxide
accumulation in the retina [39]. Furthermore, cytosolic ROS, via activa-
tion of matrix metalloproteinases [40], damage retinal mitochondrial
membrane, and further acerbate mitochondrial dysfunction [41]. Thus,ROS production by cytosolic and mitochondrial sources in a diabetic
environment appears to be closely interrelated.
7. Oxidative stress and other metabolic abnormalities
Increase in oxidative stress in diabetes and its role in the develop-
ment of diabetic complications is now well accepted. Many molecular
mechanisms are implicated in the induction of increased oxidative
stress, including auto-oxidation of glucose, impaired antioxidant de-
fense enzymes, metabolic abnormalities initiated by hyperglycemia
and damage to the mitochondria [2,15,17]. Furthermore, since diabetes
is a life-long disease, continuing cycle of metabolic stress and tissue
damage further increases free radical production. The retina and its
cells experience increased oxidative stress in diabetes, and their mito-
chondria are damaged, andmetabolic abnormalities, initiated in diabet-
ic environment are also considered as potential contributor of increase
oxidative stress. However, how thesemechanisms lead to increased ox-
idative stress and to the development of diabetic retinopathy remains
unclear.
In diabetes, activation of the polyol pathway has potential to in-
crease oxidative stress via both, decreasing intracellular antioxidant
and increasing production of ROS. Increased consumption of NADPH
by aldose reductase, the rate limiting enzyme of polyol pathways, is as-
sociatedwith decreasedGSH levels, and increased availability of NADPH
for Nox, increases the generation of intracellular oxidant species [42].
Increased accumulation of AGEs is implicated in alterations in func-
tion, activity, and degradation of both intracellular and extracellular
proteins via chemical rearrangement and cross-linking. AGEs accumula-
tion within retinal capillary cells, induce permanent abnormalities in
extracellular matrix component function and, via their recognition by
receptors, causes oxidative stress by depleting GSH and reducing
glyoxalase-1 recycling [43]. AGEs modify macromolecules and form
intra-molecular and intermolecular cross-links, and increased interac-
tions of AGEs with their receptors, RAGEs, can increase nitrative stress
in the retinal vasculature [19]. In addition, AGEs, by a sequence of mo-
lecular and biochemical pathways, activate nuclear translocation
factor-kB (NF-kB) and caspase-3, resulting in capillary cell apoptosis. Ni-
tration of proteinsmay also disrupt protein assembly and functions, and
can cause endothelial and neuronal cell apoptosis, ultimately leading to
pathological consequences and damage of cellular constituents [44].
Thus, there appears to be a close loop between AGEs and oxidative
stress.
While ROS can activate PKC, PKC activation can also result in the loss
of thiols. Modiﬁcation of PKC by increased oxidative stress can further
contribute to redox-mediated signaling events, and prolonged oxidant
exposure could result in sustained PKC activation [45]. In contrast, inhi-
bition of PKC inhibits thehyperglycemia-induced increase in free radical
production [32].
Activation of hexosamine pathway, as an alternative to glycolysis for
the utilization of hyperglycemia-induced overproduction of fructose-6-
phosphate, is also associated with endothelial cell and retinal neuron
apoptosis [46].
Many inﬂammatory mediators and leukocyte adhesion are upregu-
lated in diabetes, and diabetic retinopathy is now considered as a low
grade chronic inﬂammatory diseases [47]. Increased ROS stimulate re-
lease of inﬂammatory cytokines via activation of NF-kB, and the levels
of NF-kB are elevated in the retina and vitreous of patients with prolif-
erative diabetic retinopathy and in animal models of diabetic retinopa-
thy [48,49]. Cytokines themselves are also a good source of ROS
production, and ROS are a strong stimulus for the release of the cyto-
kines, thus suggesting a bidirectional mechanism [50,51]. In support,
antioxidants administration to diabetic rats inhibits increase in retinal
pro-inﬂammatory cytokines, and administration of cytokines in the
vitreous of normal rats, increases oxidative damage [52].
From the literature cited above, diabetes-induced major metabolic
abnormalities and oxidative stress appear to be inter-related where
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metabolic abnormalities produce increased oxidative stress (Fig. 1).
8. Antioxidant defense system
To preserve the cellular redox homeostasis, and keep the free radi-
cals in check, the cell has an efﬁcient enzymatic and non-enzymatic an-
tioxidant defense system. This antioxidant defense system is comprised
of intracellular antioxidants and enzymes, including superoxide scav-
enging enzymes, glutathione peroxidase and reductase [34,53]. Intra-
cellular antioxidants, such as glutathione and ascorbic acid neutralize
the detrimental effect of free radicals, and enzymes scavenge free radi-
cals, including superoxide radicals generated in the mitochondria,
which do not readily cross the membranes. Manganese superoxide dis-
mutase (MnSOD), a superoxide scavenging enzyme, converts intra-
mitochondrial superoxide to hydrogen peroxide, which can diffuse out
of mitochondria or further catalyzed into harmless byproducts and pro-
tectmitochondrial damage [54]. Regulation ofmitochondrial function is
controlled by nuclear-mitochondrial anterograde signaling, the signal-
ingwhich regulates the expression of nuclear encoded stress responsive
genes, forming cellular antioxidant defense system that help and pro-
tect mitochondrial function [55,56]. The cell is also equipped with a
master transcription factor, NF-E2-related factor 2 (Nrf2). Nrf2 regulates
the transcription of the enzyme critical in antioxidant defense, including
glutamate cysteine ligase for GSH biosynthesis. In diabetes, the retina
experiences compromised antioxidant defense system; the activitiesFig. 1.Diabetic environment increases production of reactive oxygen species (ROS) and also ind
kinase C (PKC), advanced glycation end products (AGEs) and hexosamine (Hexos) pathway, an
chondrial ROS, via inhibiting glyceraldehyde 3-phosphate dehydrogenase, feed into the metab
and function, which subsequently accelerates cell apoptosis, and leads to the development of rof antioxidant defense enzymes-MnSOD, glutathione peroxidase and
catalase are decreased, the transcriptional activity of Nrf2 is also subnor-
mal and mitochondrial function is compromised [57]. Furthermore, the
levels of glutathionebecome subnormal [10]. The role of oxidative stress
in the development of diabetic retinopathy is further strengthened by
the studies showing decreased expression of thioredoxin-interacting
protein, an endogenous inhibitor of thioredoxin [58], further adding
an oxidative burden to the retina.
9. Mitochondrial damage
Mitochondria, the powerhouse of the cell, are themajor endogenous
source of free radicals, but are also the targets for its damaging effects. In
the pathogenesis of diabetic retinopathy, mitochondria in retinal endo-
thelium are swollen with partial crystolysis, and they are dysfunctional,
with impaired respiration [39,41,59–61]. The role of mitochondria in
the development of diabetic retinopathy is further supported by our
studies showing the protection of the development of diabetic retinop-
athy in mice overexpressing the gene encodingmitochondrial superox-
ide dismutase,MnSOD [39]. Although it is clear thatmitochondria play a
role in the development of diabetic retinopathy, how diabetic environ-
ment damages them remains unclear, and below are some of the possi-
ble mechanism that could be function.
Experimental models (both in vitro and in vivo) have clearly shown
that generation of ROS in hyperglycemic environment is an early
event, but despite this increase, increase in ROS and damage to theuces manymetabolic abnormalities, including activation of polyol pathway (POP), protein
d production of inﬂammatory mediators. Increased ROS damagemitochondria, and mito-
olic abnormalities. Sustained accumulation of ROS damages mitochondrial DNA (mtDNA)
etinopathy.
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tended [59,61]. The possibility that cytosolic ROS, via damaging the
membrane structure of the mitochondria, decrease the mitochondrial
membrane potential [62], however, cannot be ruled out. In support,
we have shown that ROS produced in diabetic conditions progressively
damage themitochondria, and that could be contributing to the time lag
between increase in cytosolic ROS and mitochondrial dysfunction seen
in the retina and its capillary cells [17]. In diabetic retinopathy, activa-
tion of redox-sensitive gelatin matrix metalloproteinases (MMPs) is
an early event, which is followed by their accumulation in the mito-
chondria, resulting in damage of endothelial mitochondria [41]. In addi-
tion, increased lipid peroxidation can also damage mitochondrial
membrane, and retinal lipid peroxide levels are elevated in diabetes.
Increased oxidative stress can also activate redox-sensitive NF-kB,
and its activation in diabetes in the retinal endothelial cells and
pericytes is associated with their accelerated apoptosis [48]. Due to ac-
tivation of NF-kB, the expression of the inducible form of nitric oxide
synthase is increased resulting in increased nitric oxide production.
Peroxynitrite, formed by reaction between nitric oxide and superoxide
radicals interacts with mitochondria resulting in mitochondrial transi-
tion pore opening. This allows the release of cytochrome c, and activates
the apoptotic machinery [59]. Peroxynitrite levels are elevated in retina
early in diabetes and remain elevated at 14 months of diabetes in rats,
and increased nitrotyrosine can be localized in the retinal vasculature
of diabetic rats.
The coupling between the electron transport chain and ATP synthe-
sis is mediated via the proton carriers, the uncoupling proteins (UCPs),
and mild uncoupling of the inner mitochondrial membrane controls
the membrane potential and regulates mitochondrial ROS [63]. Recent
studies have shown an association between UCP1-3826A/G polymor-
phism and retinopathy in type I diabetic patients [64]. However, the
exact role of UCPs in mitochondrial homeostasis in the development
of diabetic retinopathy remains to be explored.
Mitochondria are also equipped with their own circular DNA,
mtDNA, and this small DNA is in the close proximity to the electron
transport machinery and lacks histones, making it prone to increased
oxidative damage [65]. The activity of Complex III of the electron trans-
port chain, the major source of superoxide production, is impaired in
the retina and its capillary cells in diabetes [39]. Diabetes is shown to in-
crease the levels of oxidativelymodiﬁed guanine bases (8-OHdG) in the
retinal mitochondria [66]. In addition, the number of sequence variants
is increased [60]. Although mtDNA encodes only 13 proteins, these are
essential for proper functioning of the electron transport chain and for
themitochondrial homeostasis [65]. Due to damage of mtDNA, its tran-
scription is impaired, which further compromises the function of the
electron transport, and the process results in increased ROS production
[66]. Mitochondria are equipped with efﬁcient DNA repair machinery,
which consists of nuclear DNA-encoded base excision repair (BER)
[67] andmismatch repair (MMR) enzymes. Although BER system recog-
nizes, excises and replaces small basemodiﬁcations in theDNA to repair
the oxidative damage [67], the MMR system repairs uncomplimentary
base pairs incorporated into the DNA. Diabetic environment attenuates
the ability of this machinery to repair the damage, and one of the rea-
sons appears to be thediabetes-induced poor ability of themitochondri-
al transport system to transport these repair enzymes inside the
mitochondria [68].
The essential transcription elements and the control sites for replica-
tion of mtDNA are localized on a non-coding region of the mtDNA, the
D-loop region. We have shown that in diabetes, this unwound region
is highly vulnerable, and is damaged more extensively than rest of the
circular mtDNA [69]. Due to damage to the main transcription site of
the mtDNA, transcription of the genes responsible for the electron
transport is decreased, resulting in increased production of superoxide
radicals. To make the bad situation worse, the binding of mtDNA repli-
cation enzyme polymerase gamma (POLG) at the D-loop is also attenu-
ated, and mtDNA copy numbers are decreased [70]. Thus, suboptimalmtDNA transcription and biogenesis decrease the activity of the
electron transport chain and increase superoxide radicals, and these su-
peroxide radicals continue to fuel into the vicious cycle of free radicals.
As diabetic retinopathy is a progressing disease, we have shown that
during the initial stages of the disease, the transcription of the genes im-
portant in mtDNA biogenesis and repair is increased to overcome
diabetes-induced increase in ROS, but as the disease progresses, the
system gets overwhelmed, andmtDNA biogenesis and the repair mech-
anisms fail to keep upwith the demand, and break apart [61]. However,
regulation of increased mitochondrial superoxide accumulation by
overexpression of the gene encodingmitochondrial superoxide dismut-
ase, Sod2, in mice, which protects from the development of diabetic ret-
inopathy, also prevents decreasedmtDNA transcription and replication,
suggesting a critical role of mitochondrial homeostasis in the develop-
ment of diabetic retinopathy [39,69,71] (Fig. 2).
10. Epigenetic modiﬁcations, oxidative stress and
diabetic retinopathy
In the pathogenesis of diabetic retinopathy, the expression of many
genes associated with various metabolic abnormalities including
inﬂammation and oxidative stress, are altered in the retina and its
capillary cells [16,57]. Emerging studies have now documented that
the gene expression is also regulated by the environmental factors and
life style, and epigenetic modiﬁcations are now implicated in many
chronic diseases. These epigenetic changes, without changing the DNA
sequence, can control gene activity, and this dynamic process of
transcriptional activation or repression depends on the recruitment of
protein complexes that alter chromatin structure via enzymatic modiﬁ-
cations of histone tails and nucleosome remodeling, altering the acces-
sibility of transcription factors to the DNA [72]. Recent studies have
suggested that these epigenetic changes could explain the chronic and
persistent microvascular complications of diabetes, including retinopa-
thy [11,12,18,58,70,73,74]. Recent studies have shown an association
between the polymorphism in the gene that encodes histone methyl-
transferases, SUV39H2, and diabetic retinopathy [75]. Others have also
shown signiﬁcant increase in retinal histone acetylation in diabetes
[76]. Thus, the data implicating the role of epigenetics in the develop-
ment of diabetic retinopathy remains ambiguous.
Contrary to the clinical data, experimentalmodels have clearly dem-
onstrated the role of epigenetics in diabetic retinopathy, especially, in
the regulation of oxidative stress. Our studies using in vitro and in vivo
models of diabetic retinopathy have shown Sod2, is epigenetically
modiﬁed with increased methylation of H4K20 and acetylation of
H3K9, facilitating the binding of NF-kB at its promoter/enhancer [74].
In addition, the function of the master regulator, Nrf2, is also affected
by the epigenetic modiﬁcation, we have shown that the histones at
the promoter of the intracellular inhibitor of Nrf2, Kelch-like ECH asso-
ciated protein 1 (Keap1), are modiﬁed, and this alters the binding of
transcriptional factor Sp1 [12]. Increased Keap1 compromises the tran-
scriptional activity of Nrf2 by restraining it in the cytosol. Histones at the
promoter of the enzyme critical in biosynthesis of the intracellular anti-
oxidant GSH are also modiﬁed in diabetes, resulting in decreased bind-
ing of the transcriptional factor Nrf2, and decreasing its transcription
[11,12,77]. In addition, in diabetes, thioredoxin-interacting protein is
shown to promote epigenetic alterations at the promoter of retinal
cyclooxygenase-2 [58]. Thus, histone modiﬁcations appear to play an
important role in the maintenance of the antioxidant defense system
of the retina in diabetes. Moreover, epigenetic modiﬁcations also facili-
tate the damage to the retinal mitochondria; hypo-methylation of
H3K9, with concomitant hyper-acetylation of H3K9 at retinal MMP-9
promoter is also implicated in its activation of in diabetes, and MMP-9
is shown to initiate the apoptotic machinery by damaging the
mitochondria [78].
In addition to histone modiﬁcations, methylation status of the cyto-
sine in the DNAmolecule also regulate gene transcription as DNA is not
Fig. 2.Diabetes activates NADPH oxidase (NOX) complex, and increased oxidative stress alters the cellular gene expression, including that of matrix metalloproteinase 9 (MMP-9),
mitochondrial superoxide dismutase (MnSOD), DNA methyltransferase 1 (Dnmt1) and mitochondrial transcription factor A (TFAM). Due to abnormalities in the chaperons
(Heat shock protein, Hsp70) and mitochondrial membrane transport system (TOM and TIM), mitochondrial accumulation of Dnmt1 and MMP-9 are increased and that of
TFAM is decreased. Increased mitochondrial MMP-9 damages mitochondrial connexin 43, and increases pore permeability, facilitating the leakage of cytochrome c (Cyt
c) into the cytosol and activating the apoptotic machinery, and decreased accumulation of TFAM in the mitochondria impairs mtDNA biogenesis. Due to increased Dnmt1 in
the mitochondria, mtDNA is hypermethylated and its transcription is impaired, and this compromises the electron transport system generating more free radicals. Due to cytoplasmic
degradation of TFAM by oxidative stress, its mitochondrial levels are decreased andmitochondrial biogenesis is impaired, and this further fuels into the vicious cycle of ROS. Tomake the
bad situation worse, the activity of mitochondrial scavenging enzyme is also decreased, and free radicals continue to feed into the vicious cycle.
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mental stimuli by modifying its properties in adapting to the
changes. Methylation of the CpG changes protein-DNA interactions
leading to alterations in chromatin structure, and this interferes
with the binding of transcriptional machinery, resulting in gene
suppression [79]. The methylation process is carried out by DNA
methyl transferases (Dnmts), a family with 5 members, out of
which only Dnmt1, Dnmt3a and Dnmt3b are catalytically active. Di-
abetes activates Dnmts in the retina, and CpG islands at the regula-
tory region of POLG are hypermethylated decreasing its binding
with the D-loop region of mtDNA, interfering with mtDNA biogene-
sis [70]. In addition to the nuclear DNA, mtDNA is also susceptible
to epigenetic modiﬁcations as this small DNA has ~450 CpG sites
and ~4500 cytosine residues at non-CpG sites. Increased mtDNA
methylation is observed in chronic diseases, including cancer [80],
and our recent studies have shown that in diabetes, increased
Dnmt1 expression in the retinal mitochondria hypermethylates
its mtDNA [81]. Due to hypermethylation of the D-loop region,
mtDNA transcription is impaired and electron transport chain is
compromised, and mitochondrial homeostasis continues to dis-
turbed. Thus, although mtDNA methylation ﬁeld is still in its infan-
cy, it holds a good promise for understanding the pathogenesis of
diabetic retinopathy.
In addition to histone modiﬁcations and DNA methylation, small
non-coding RNAs (miRNAs) are also altered in diabetes, and these
miRNAs can regulate post-transcriptional gene expression by binding
to their target messenger RNAs. Models of diabetic retinopathy have
shown that upregulation of vascular endothelial growth factor (VEGF)
is associated with the downregulation of miR-126, miR-146a and
miR-200b and upregulation ofmiR-195 downregulates Sirt1 [82,83]; as
mentioned in the previous section, Sirt1 plays an important role in reg-
ulation of NF-kB, a transcriptional factor associated with the regulation
ofMMP-9 and Sod2 [74,78,84].Thus, the role of epigenetic modiﬁcation is now becoming more
evident than previously appreciated.11. Therapeutic implications
Here we have presented overwhelming evidence that oxidative
stress is increased in the retina in diabetes, and increased oxidative
stress plays a major role in the development of diabetic retinopathy.
As in diabetic environmentmultiplemechanisms can increase oxidative
stress, and different antioxidants can either inhibit the production of
ROS, or neutralize superoxide radicals, or augment antioxidants defense
system, many antioxidants have been tried in animal studies.
Administration of green tea, which is rich in polyphenols, in addition
to inhibiting increased retinal ROS levels, also provides neuroprotection,
and ameliorates diabetes-induced abnormalities in blood-retinal break-
down and electroretinograms [85]. It is also shown to attenuate histopa-
thology characteristic of diabetic retinopathy, including the formation of
degenerative capillaries and formation of pericyte ghosts.
Lipoic acid, an organosulfur compound capable of thiol-disulﬁde ex-
change and scavenging ROS, decreases retinal levels of VEGF, 8-OHdG
and nitrotyrosine and ameliorates NF-kB activation in diabetic rats
[86]. Lipoic acid is also considered as a mitochondrial function and
named them “mitochondrial nutrient”, as it can directly or indirectly
protect oxidative damage to the mitochondria and helps glutathione
to maintain a healthy cellular redox state, and its administration
prevents mitochondrial dysfunction and capillary cell apoptosis and
the development of diabetic retinopathy in rats [86].
Benfotiamine, a lipid soluble thiamine (vitamin B1), prevents
hyperglycemia-induced pericyte-endothelial cell interactions [87]. In
diabetic rats, Benfotiamine has been shown to inhibit the development
of histopathology characteristic of diabetic retinopathy via inhibiting
the major biochemical pathways implicated in its pathogenesis [88].
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lowering properties, to diabetic rats is shown to provide partial beneﬁt
to the development of diabetic retinopathy; it inhibits the pericyte loss
in the retinal vasculature, but does not reduce the formation of
microaneurysms and acellular capillaries [89]. Trolox, a water soluble
analog of vitamin E, reduces membrane lipid peroxidation and partially
prevents the loss of pericytes in diabetic rats via reducing membrane
lipid peroxidation [90]. However, no additional follow up studies have
been reported for, both nicanartine and trolox.
Supplementation of rat diet with vitamins C and E prevents increase
in oxidative stress in the retina by ameliorating decrease in the antiox-
idant defense machinery, and also decreasing the production of super-
oxide radicals. This amelioration in retinal oxidative stress is
accompanied by decreased formation of both degenerative capillaries
and pericyte ghosts in the retinal vasculature [34,53]. However, when
vitamins C and E administration is supplemented by other antioxidants,
including Trolox, N-acetyl cysteine, β-carotene and selenium, this
multi-antioxidantmixture prevents activation of PKC, reduces oxidative
stress and ameliorates the formation of microvascular lesions in the ret-
ina, the multi-antioxidants abrogate the diabetes-induced increases in
retinal PKC and nitric oxide [53]. A carotenoid rich diet, which is in clin-
ical trials for ‘Diabetes Vision Function’, prevents retinal capillary cell
apoptosis and vascular and functional damage in diabetic rats [91]. Ad-
ministration of the nutritional antioxidants that have been demonstrat-
ed to slow the progression of age-related macular degeneration in
patients, protects the retina from diabetes-induced increased oxidative
damage and prevents the development of retinal histopathology char-
acteristic of diabetic retinopathy in rodents [92]. These results from ex-
perimental model have clearly demonstrated that this multi-factorial
disease responds better to the diverse antioxidant mixture than just
the vitamins C and E.
Literature cited above clearly suggest the importance of mitochon-
drial homeostasis in the development of diabetic retinopathy; and we
have shown that overexpression of Sod2 in mice prevents diabetes-
induced mitochondrial damage in retinal capillary cells, including bio-
genesis and dysfunction, and also protects the retinal vasculature from
the development of histopathology [39]. MnSOD mimics, Tempol and
M40403 are shown to ameliorate endothelial dysfunction and abnor-
malities in endoneural blood ﬂow [93]. We have shown that MnSOD
mimic, MnTBAP, protects cells [59]. Suppression ofMMP-9 in mice pro-
tects diabetes-induced damage to the retinal mitochondrial structure
and function, and ameliorates the formation of degenerative capillaries
in the retinal vasculature [41]. In addition, inhibition of Nox2 activation
by regulation of its upstream signaling axis, Tiam1-Rac1, ameliorate
glucose-induced capillary cell apoptosis in retinal endothelial cells
[17]. Thus, prevention of mitochondrial damage by suppression of the
damaging MMP-9, or by preventing the accumulation of superoxide
radicals by overexpressing Sod2 protects the development of retinopa-
thy in rodents.
Administration of curcumin, a polyphenol with potent antioxidant
and anti-inﬂammatory effects, or Zeaxanthin, a dietary carotenoid,
which is speciﬁcally concentrated in the retina, is shown to attenuate
increase in retinal oxidative stress and proinﬂammatory markers in di-
abetic rats [94,95]. Peroxynitrite decomposition compound, FP15, ame-
liorates diabetes-induced increased leukocyte entrapment in the retinal
microcirculation [96], and PARP inhibitor PJ-34, prevents the early
lesions of diabetic retinopathy [97].
Although there is awealth of data supporting the beneﬁcial effects of
antioxidants in the development of diabetic retinopathy, clinical studies
have yet to demonstrate their beneﬁts. Vitamin E is shown to ameliorate
retinal hemodynamic abnormalities in diabetic patients [98], and oral
administration of α-lipoic acid with genistein and vitamins for
30 days is shown to improve ERG oscillatory potential in patients with
proliferative diabetic retinopathy [99]. Antioxidant properties contain-
ing calcium dobesilate and pycnogenol reduce the progression of dia-
betic retinopathy [100,101]. Our recent double masked study using amulti-component nutritional formula (vitamins C, D3, and E, zinc
oxide, eicosapentoenoic acid, docosahexaenoic acid, alpha-lipoic acid,
coenzyme Q10, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, res-
veratrol, turmeric root extract, green tea leaf) has shown encouraging
results, as this multi-component nutritional formula can improve visual
function and reduce serum inﬂammatory proteins in diabetic patient
[102]. However, others have not observed any signiﬁcant association
between serum levels of major dietary antioxidants and retinopathy
[103]. Also, a retrospective study in type II diabetic patients, based on
a single 24-hour diet recall, fails to show any association between
antioxidant supplementation (vitamins C and E, and β-carotene) and
decrease in the severity of retinopathy [104].
Thus, despite encouraging results from the animal models, due to
lack of well-designed longitudinal cohort studies, clinical studies have
been inconclusive. This discrepancy could be the time of intervention
for this slow progressing disease as DCCT/EDIC studies have shown
the importance of the prior damage to the retina in the outcome of
the tight glycemic control [8] Some of the other factors including the
dose of the antioxidants and the duration of their administration in dia-
betic patients, could also inﬂuence the clinical outcome. In addition, al-
though vitamin E is an antioxidant, it could also exhibit pro-oxidant
effects and further acerbates oxidative stress [105]. Also the possibility
that due to a well-deﬁned blood-retinal barrier, transport of these anti-
oxidants to the retina could be a limiting factor, cannot be ruled out. De-
spite these limitations, we believe that encouraging animal results and a
very limited clinical data, strongly suggests for some longitudinal cohort
studies and clinical trials.
Evidence provided above clearly shows the importance of epigenetic
modiﬁcations in the development of diabetic retinopathy. Most of the
inhibitors for histone acetylation have strong antioxidant properties.
Resveratrol, a potent inhibitor of histone deacetylases, which activates
Sirt1 and improves mitochondrial function, prevents diabetes-induced
decrease in retinal Sirt1 and hyperacetylation of NF-kB [84]. In addition,
epigallocatechin-3-gallate is considered a strong histone acetylase in-
hibitor, and shown to inhibit NF-kB activation [106]. In the development
of diabetic retinopathy, hyperacetylation of NF-kB activates MMP-9,
which is associated with retinal mitochondrial dysfunction and endo-
thelial cell apoptosis [84]. Curcumin and genistein are also shown to
regulate the epigeneticmachinery [107]. Dnmt is activated in the *retina
in diabetes, and activated Dnmt is shown to damage retinal mitochon-
dria [70]. Dnmt inhibitors are now being in clinical trials for chronic
diseases; FDA approved Dnmt inhibitor 5-azacytidine and 5-aza-20-
deoxycitidine, are now in use for myeloid cancers and cutaneous T cell
lymphoma [108]. With emerging data showing the importance of epi-
genetics in the development of diabetic retinopathy, prevention of
such modiﬁcations could also prove an avenue to inhibit the develop-
ment of retinopathy in diabetic patients.
12. Conclusion and perspective
Vision is the most indispensable means of communication, and dia-
betic retinopathy remains the leading cause of robbing a young patient
of this valuable mean. The etiology of this slow progressing disease is
very complex as number of metabolic, physiological and functional ab-
normalities have been identiﬁed playing important role in its pathogen-
esis. Despite extensive research in the ﬁeld, maintaining tight glycemic
control still remains the most viable option for preventing the develop-
ment/progression of diabetic retinopathy, but tight glycemic control
comes with added burdens of possible hypoglycemia and weight gain.
Diabetes initiates a number of metabolic abnormalities in the retina,
and oxidative stress is increased, which itself can also feed into these
metabolic abnormalities. Mitochondria are damaged with a suboptimal
electron transport chain, and damage to mtDNA further compromises
the electron transport chain. Tomake the bad systemworse, scavenging
of free radicals and repair of the damaged mtDNA are also compro-
mised, and free radicals continue to accumulate. Genes encoding
Fig. 3. Schematic representation shows diabetes-induced metabolic disturbances, reactive oxygen species (ROS), and epigenetic modiﬁcations. Increase in ROS degrades biomolecules
(proteins, nucleic acid, lipids and carbohydrate), and epigenetic modiﬁcations (via histone modiﬁcations and DNAmethylation) and miRNAs alter gene expression of proteins associated
with maintain a redox balance. Capillary cell apoptosis is accelerated resulting in the development of diabetic retinopathy.
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the antioxidant defense system (Sod2, Keap-1 etc.) are also epigenetical-
ly modiﬁed, further adding burden to the self-propagating vicious cycle
of free radicals. Fig. 3 depicts the interrelationship between oxidative
stress, metabolic disturbances and epigenetic modiﬁcations. Although
experimental data with the use of antioxidants have been encouraging
in preventing/slowing diabetic retinopathy, with the overwhelming
data demonstrating the role of oxidative stress in its development,
well-controlled longitudinal trial with antioxidants is warranted. Anti-
oxidants could target multiple steps of oxidative stress and mitochon-
drial damage, and should be a welcoming sign for diabetic patients in
preventing this sight-threatening disease.
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